Introduction: Healthcare Demand & Artemis’s Strategic Positioning

The Indian private healthcare delivery ecosystem continues to experience structural tailwinds. Driven by rising incidence of non-communicable diseases, expanding health insurance penetration, growing domestic per-capita disposable income, and a strong resurgence in international medical tourism, organized hospital chains are expanding operational capacity while optimizing yield per bed.

Against this macroeconomic backdrop, Artemis Medicare Services Ltd. (NSE: ARTEMISMED | BSE: 542919) published its Q1 FY27 financial results for the quarter ended June 30, 2026. The quarterly performance highlights operational momentum at its flagship quaternary-care hospital in Sector-51, Gurugram, supported by steady contributions from its specialized cardiac care subsidiary, Artemis Cardiac Care Private Limited.

Investors tracking the healthcare sector are closely analyzing Artemis Medicare’s capacity utilization trends, margin profile, international patient mix, and capital deployment strategy. Beyond the top-line and bottom-line expansion, the key takeaway from the August 3, 2026 Board meeting was the formal approval of a ₹160 to ₹180 crore brownfield expansion plan to construct Tower IV at the flagship Gurugram campus. This addition will add over 200 specialized beds dedicated to high-margin quaternary pediatric care and advanced gynecology services.

+-----------------------------------------------------------------------------------+
|                        ARTEMIS MEDICARE Q1 FY27 AT A GLANCE                       |
+-----------------------------------------------------------------------------------+
|  Consolidated Revenue  : ₹287.32 Cr   (+12.69% YoY | +2.90% QoQ)                |
|  Consolidated PAT      : ₹31.44 Cr    (+48.33% YoY | +3.84% QoQ)                |
|  EBITDA Margin         : 19.64%       (Expanded by 305 bps YoY)                  |
|  Flagship Capacity     : 65.7% Utilization Rate across ~800 Gurugram Beds       |
|  Capex Trigger         : ₹160-180 Cr Tower IV Project (200+ Beds Approved)        |
+-----------------------------------------------------------------------------------+

Company Profile & Operational Infrastructure

Established in 2007 by the promoters of the Apollo Tyres Group (led by Mr. Onkar Kanwar), Artemis Medicare Services Ltd. was the first hospital in Gurugram to receive joint accreditation from Joint Commission International (JCI) and the National Accreditation Board for Hospitals & Healthcare Providers (NABH).

Core Business Model & Healthcare Footprint

Artemis operates primarily as a multi-specialty and quaternary healthcare service provider. The company’s clinical expertise is centered on high-acuity medical disciplines, including Cardiology & Cardiac Surgery, Oncology (Medical, Surgical & Radiation), Neurosciences, Orthopedics & Joint Replacement, Organ Transplants (Liver & Kidney), and Renal Sciences.

+-----------------------------------------------------------------------------------+
|                      GEOGRAPHIC & OPERATIONAL BED DISTRIBUTION                    |
+-----------------------------------------------------------------------------------+
|  Flagship Campus (Gurugram, Sector-51)  : ~800 Beds (Occupancy: 65.7%)             |
|  Regional Presence (Raipur, Chhattisgarh): ~300 Beds                              |
|  Upcoming Asset (Vimhans Artemis, Delhi) : 650+ Beds (Phased, Ops by FY29)        |
|  Approved Addition (Tower IV, Gurugram)  : 200+ Beds (~2 Years Execution)         |
+-----------------------------------------------------------------------------------+

• Flagship Campus (Gurugram, Haryana): Multi-specialty hospital spread across 9 acres in Sector-51, Gurugram, housing ~800 beds with advanced surgical suites, medical ICUs, and specialized diagnostic infrastructure.

• Regional Assets: Operates a ~300-bed facility in Raipur, Chhattisgarh, extending tertiary care access into Central India.

• Vimhans Artemis Hospital (Nehru Nagar, New Delhi): A major upcoming asset under development that will feature 650+ beds in a phased operational roll-out, with primary commissioning targeted for FY29.

• Artemis Cardiac Care (ACCPL): A specialized subsidiary running asset-light cardiac care centers and catheterization labs in tier-2 and tier-3 cities.

• Artemis Lite & Solace Units: Multi-specialty neighborhood clinics and boutique day-care centers catering to localized primary care and surgical needs.

Q1 FY27 Financial Highlights: Detailed P&L Breakdown

For the quarter ended June 30, 2026, Artemis Medicare Services Ltd. posted growth across both standalone and consolidated balance sheets. The statutory auditors, T R Chadha & Co LLP, conducted a limited review report issuing an unmodified opinion.

Standalone vs. Consolidated Performance Table

Operational Performance, ARPOB, and Geographic Breakdown

Healthcare institutional analysis requires examining operational metrics like Average Revenue Per Occupied Bed (ARPOB), patient footfalls, and international patient contributions.

+-----------------------------------------------------------------------------------+
|                        Q1 FY27 REVENUE BY CUSTOMER LOCATION                       |
+-----------------------------------------------------------------------------------+
|  Domestic Revenue (India)          : ₹21,081.83 Cr (73.37% Share | +14.25% YoY) |
|  International Revenue (Ex-India)  : ₹7,650.52 Cr  (26.63% Share | +8.62% YoY)  |
|  Total Consolidated Operational Rev: ₹28,732.35 Cr (100.0% Share | +12.69% YoY) |
+-----------------------------------------------------------------------------------+

Geographical Revenue Contribution

Disclosures under Ind AS 108 show the geographical origin of Artemis Medicare’s patient revenues:

• Domestic Operations (India): Consolidated revenue from domestic patients reached ₹21,081.83 lakh in Q1 FY27, compared to ₹18,452.87 lakh in Q1 FY26, representing a YoY growth of 14.25%. Domestic patient footfalls were bolstered by higher surgical volumes in oncology, orthopedics, and cardiology.

• International Operations (Medical Tourism): Revenue derived from overseas patients traveling to India for complex quaternary procedures rose to ₹7,650.52 lakh in Q1 FY27, compared to ₹7,043.22 lakh in Q1 FY26—a YoY increase of 8.62%. International medical travelers contributed 26.63% of total operating revenue during the quarter.

• Asset Location: Non-current operational assets are located entirely in India, valued at ₹1,03,160.79 lakh as of June 30, 2026.

Capacity Utilization & Bed Economics

During Q1 FY27, capacity utilization at the flagship Gurugram hospital stood at 65.7% across its ~800 operational beds. The company maintained steady yield expansion via higher-acuity surgical cases and robotic procedure adoption, driving Average Revenue Per Occupied Bed (ARPOB) growth higher.

Major Strategic Expansion: Tower IV at Gurugram Flagship

The core corporate update accompanying the Q1 FY27 financial results is the formal authorization of the Tower IV Expansion Project.

+-----------------------------------------------------------------------------------+
|                         TOWER IV EXPANSION PROJECT DETAILS                        |
+-----------------------------------------------------------------------------------+
|  Location             : Sector-51, Gurugram (Flagship Campus)                     |
|  Target Capacity      : 200+ Additional Inpatient Beds                            |
|  Focus Clinical Units : Quaternary Pediatric Care & Advanced Women's Health       |
|  Capital Expenditure  : ₹160 Crore to ₹180 Crore                                  |
|  Financing Structure  : Internal Cash Accruals and Bank Debt                      |
|  Completion Horizon   : ~2 Years (Phased Commissioning)                           |
+-----------------------------------------------------------------------------------+

Detailed Rationale & Strategic Scope:

1. Focus on Quaternary Pediatrics: The expansion addresses rising regional and international demand for specialized pediatric sub-specialties. Tower IV will house Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), pediatric super-specialties, pediatric cardiac surgery, and emergency pediatric trauma bays.

2. Advanced Gynecology & Obstetrics: The facility will expand capacity in high-risk pregnancy management, maternal-fetal medicine, reproductive medicine (IVF/ART), gynecologic oncology, urogynecology, and genetics.

3. Financial Return Profile: Brownfield expansions generally deliver higher Return on Capital Employed (ROCE) and shorter gestation periods compared to greenfield developments because central diagnostic suites, emergency rooms, administrative offices, and pharmacy supply chains are already established.

Financial Health, Balance Sheet & IFC Funds Utilization

International Finance Corporation (IFC) Equity Investment

As disclosed in Note 5 of the financial statements, Artemis Medicare issued 33,000 Compulsorily Convertible Debentures (CCDs) totaling ₹33,000 lakh (₹330 crore) to the International Finance Corporation (IFC) on a preferential basis. On November 15, 2025, these debentures converted into 1,89,62,247 equity shares.

• Capital Utilization: Out of the total ₹330 crore proceeds, ₹15,434 lakh (including ₹1,745 lakh deployed during Q1 FY27) has been spent on clinical capacity expansions.

• Treasury Cushion: The remaining balance continues to be held in interest-bearing fixed bank deposits, providing liquidity for the ongoing construction of Tower IV and the Vimhans project.

Debt Profile & Finance Cost Reduction

Due to prudent capital structure management and conversion of debentures, Artemis reduced its debt service burden. Standalone finance costs decreased by 9.67% YoY to ₹642.20 lakh, while consolidated finance costs fell 12.49% YoY to ₹645.99 lakh.

+-----------------------------------------------------------------------------------+
|                         BALANCE SHEET & LIQUIDITY DRIVERS                         |
+-----------------------------------------------------------------------------------+
|  Paid-Up Share Capital  : ₹1,583.06 Lakhs (Face value ₹1 per share)              |
|  Consolidated Reserves  : ₹84,995.12 Lakhs (Other Equity as of FY26)              |
|  Finance Cost Trend     : Down -12.49% YoY (Consolidated Interest Savings)        |
|  IFC Treasury Reserve   : ~₹175+ Crore deployed in Fixed Bank Deposits             |
+-----------------------------------------------------------------------------------+

Margin Analysis & Operating Efficiency

A key highlight of Artemis’s Q1 FY27 performance was margin expansion:

• Operating Costs Control: Consolidated operating costs (medical consumables, surgical supplies, and doctor fees) grew by 6.68% YoY to ₹16,776.44 lakh, well below the 12.69% top-line revenue growth rate. This generated positive operating leverage.

• Employee Cost Trajectory: Employee benefit expenses increased by 11.55% YoY to ₹4,283.64 lakh, reflecting annual clinical staff increments and new nursing hires.

• EBITDA Expansion: Consolidated EBITDA expanded by 33.48% YoY to ₹5,644.21 lakh, pushing EBITDA margins up by 305 basis points YoY to 19.64%.

+-----------------------------------------------------------------------------------+
|                    CONSOLIDATED MARGIN EXPANSION TRAJECTORY                       |
+-----------------------------------------------------------------------------------+
|  Q1 FY26 EBITDA Margin : 16.59%  ====================>                            |
|  Q1 FY27 EBITDA Margin : 19.64%  ===========================> (+305 bps YoY)     |
|  Primary Margin Drivers : Higher Surgical Case Mix + International Traffic + ARPOB|
+-----------------------------------------------------------------------------------+

Subsidiary Performance: Artemis Cardiac Care (ACCPL)

Artemis Cardiac Care Private Limited (ACCPL) operates asset-light cardiac care programs in tier-2 and tier-3 locations in partnership with local regional hospitals.

ACCPL Financial Contribution (Q1 FY27):

• Total Assets: ₹2,260.47 lakh as of June 30, 2026.

• Total Operating Revenue: ₹532.06 lakh for the quarter.

• Net Profit After Tax (PAT): ₹37.75 lakh.

• Total Comprehensive Income: ₹37.33 lakh.

While ACCPL accounts for a modest share of consolidated earnings, its profitable model provides brand presence across regional markets, creating a referral pipeline for high-complexity surgeries at the flagship Gurugram hospital.

Competitor Benchmark & Industry Comparison

To evaluate Artemis Medicare’s market standing, we compare its key operational and valuation metrics against listed Indian hospital peers:

Peer metrics derived from public exchange filings and market data.

Key Takeaways from Peer Benchmarking:

1. Valuation Multiple Discount: Artemis Medicare trades at a trailing P/E of ~44.6x, representing a valuation discount relative to large-cap peers like Max Healthcare (72.1x) and Apollo Hospitals (65.8x).

2. Margin Catch-Up: Artemis’s Q1 FY27 EBITDA margin expansion to 19.64% narrows the margin gap with national hospital networks.

3. Growth Runway: With ~1,100 active beds and over 850 beds in the execution pipeline (Tower IV + Vimhans Delhi), Artemis boasts a strong capacity expansion path relative to its current market capitalization.

10. Shareholding Pattern & Institutional Activity

Equity Ownership Structure (Quarter Ended June 2026)

Technical Analysis & Market Trading Dynamics

Following the Q1 FY27 earnings release on August 3, 2026, Artemis Medicare’s share price traded on the NSE and BSE:

+-----------------------------------------------------------------------------------+
|                        TECHNICAL & MARKET METRICS SUMMARY                         |
+-----------------------------------------------------------------------------------+
|  Current Stock Price  : ~₹298.50 - ₹303.00 per share                              |
|  52-Week Range        : ₹203.35 (Low) to ₹308.00 (High)                           |
|  Market Capitalization: ~₹4,725 Crore to ₹4,790 Crore                             |
|  Key Technical Trend  : Trading near 52-week highs in a bullish continuation pattern|
|  Technical Support    : Support I: ₹278.00 | Support II: ₹262.00                       |
|  Technical Resistance : Resistance I: ₹308.00 | Resistance II: ₹325.00                |
+-----------------------------------------------------------------------------------+

• 52-Week High / Low: The stock recently reached a 52-week high of ₹308.00, rising from a 52-week low of ₹203.35.

• Moving Averages: The stock trades comfortably above its 50-day Simple Moving Average (~₹268) and 200-day Simple Moving Average (~₹242), signalling upward trend momentum.

• Volume Profile: Trading volumes expanded during late July and early August 2026, indicating institutional accumulation ahead of and following the earnings report.

SWOT Analysis: Artemis Medicare Services Ltd.

+-----------------------------------------------------------------------------------+
|                                  SWOT MATRIX                                      |
+-----------------------------------------------------------------------------------+
| STRENGTHS                                 | OPPORTUNITIES                         |
| • Strong JCI/NABH-accredited flagship asset| • Tower IV brownfield expansion       |
| • Robust international patient revenue   |   adding 200+ specialized beds        |
| • Margin expansion (EBITDA at 19.64%)     | • Vimhans Delhi project (650+ beds)   |
| • Financial backing from IFC debentures   | • Asset-light expansion via ACCPL     |
+-------------------------------------------+---------------------------------------+
| WEAKNESSES                                | THREATS                               |
| • High geographic concentration in NCR    | • Senior clinician retention & costs  |
| • Slower gestation in regional clinics    | • Regulatory price caps on implants   |
| • Dilution impact from share conversions  | • Intensifying hospital competition   |
+-----------------------------------------------------------------------------------+

Comprehensive Risk Factor Evaluation

Investors considering Artemis Medicare Services Ltd. should evaluate key risk categories:

1. Geographic Concentration Risk: The flagship Gurugram hospital generates over 85% of total revenue. Any localized operational disruption or regional economic downturn could affect financial performance.

2. Clinical Talent Cost Inflation: The market for skilled surgeons, specialists, and nursing staff in the National Capital Region is highly competitive. Wage inflation could increase employee benefit expenses.

3. Execution Delay in Capex Projects: Developing Tower IV (~₹180 Cr investment) and Vimhans Artemis (650+ beds) requires strict timeline execution and regulatory approvals. Delays could push back project yields.

4. Regulatory and Price Ceiling Risks: Regulatory mandates capping prices on essential drugs, stents, orthopedic implants, or diagnostic services could affect operating margins.

Long-Term Growth Drivers & Strategy

Artemis’s long-term thesis rests on four structural pillars:

+-----------------------------------------------------------------------------------+
|                         FOUR PILLARS OF FUTURE GROWTH                             |
+-----------------------------------------------------------------------------------+
|  1. Capacity Scaling    : Expanding total bed network toward 2,000+ beds          |
|  2. Clinical Mix      : Shifting volume to complex robotics, oncology, and ICUs   |
|  3. Medical Tourism   : Expanding international patient outreach in Asia & Africa  |
|  4. Tier-2/3 Expansion: Scaling asset-light cardiac centers via ACCPL             |
+-----------------------------------------------------------------------------------+

Analyst View & Investment Thesis

Bull Case vs. Bear Case

The Bull Case:

• Strong Profit Momentum: PAT grew 48.3% YoY in Q1 FY27, showing that operating leverage is taking effect as revenues scale.

• Capitalized Expansion: Brownfield addition of 200+ beds in Gurugram plus 650+ beds at Vimhans will nearly double operational bed capacity over the medium term.

• Institutional Sponsorship: Equity participation by IFC and strong promoter backing provide institutional governance and capital stability.

The Bear Case:

• Valuation Multiples: At ~44.6x P/E, near-term growth is largely priced into the stock.

• Gestation Drag: Capital expenditures for new projects may briefly lower Return on Equity (ROE) until new beds reach optimal occupancy rates.

Investor Suitability

Artemis Medicare offers an appealing option for growth-oriented investors seeking targeted exposure to India’s private healthcare sector, particularly those looking for mid-cap expansion potential alongside large-cap hospital peers.

Conclusion

Artemis Medicare Services Ltd. delivered a strong performance in Q1 FY27, characterized by a 12.69% YoY increase in consolidated revenue to ₹287.32 crore and a 48.33% surge in net profit to ₹31.44 crore. Operating margin expansion to 19.64%, steady international patient traffic, and reduced interest expenses highlight improving operational efficiency.

With the approval of the ₹180 crore Tower IV project in Gurugram and the long-term pipeline at Vimhans Delhi, Artemis Medicare is steadily building out its clinical footprint. Investors should monitor project execution timelines, international patient volumes, and margin sustainability in upcoming quarters.

Disclaimer

This article is written strictly for educational and informational purposes and does not constitute financial advice, an investment recommendation, or an endorsement to buy or sell securities. Stock market investments carry inherent market risks. Readers should consult a certified financial advisor before making any investment decisions.